BCell Solutions is commercializing its pipeline of patented and patent pending immunotherapies to treat various forms of chronic inflammatory diseases, including autoimmune and neurodegenerative diseases, and some cancers. R&D has reached an advanced pre-clinical stage, having now completed multiple rounds of drug synthesis, successful toxicity testing using mice, dog and human stem cells, and multiple rounds of in vivo and in vitro animal testing and human in vitro cell testing to validate use of our immunotherapies for the treatment of various diseases, many of which currently have no highly successful therapeutic treatment strategy. R&D to date has been supported by founder investments and non-dilutive grant funding. We are opening a seed funding round to support additional R&D activities, including Phase 0 trials, and also seeking collaboration and out-licensing opportunities with pharmaceutical partners to support completion of pre-clinical work and transition to clinical trials.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
BCS-C01 Immunotherapy and Follow-on Pipeline
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):